

Title (en)

ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR INHIBITION OF INFLAMMATION

Title (de)

ANTICXCL9-, ANTI-CXCL10-, ANTI-CXCL11-, ANTI-CXCL13-, ANTI-CXCR3- UND ANTI-CXCR5-WIRKSTOFFE ZUR HEMMUNG VON ENTZÜNDUNGEN

Title (fr)

AGENTS ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 ET ANTI-CXCR5 POUR L'INHIBITION DE L'INFLAMMATION

Publication

**EP 2866830 A4 20151209 (EN)**

Application

**EP 12880044 A 20120627**

Priority

US 2012044464 W 20120627

Abstract (en)

[origin: WO2014003742A1] Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, or (2) inhibits the interaction between CXCR3 and CXCL9, CXCL10 or CXCL11, or between CXCR5 and CXCL13, or (3) inhibits a biological activity of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, wherein the agent comprises an antibody, antibody fragment, short interfering RNA (siRNA), aptamer, synbody, binding agent, peptide, aptamer-siRNA chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector.

IPC 8 full level

**A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61P 29/00** (2006.01)

CPC (source: EP)

**A61P 1/04** (2017.12); **A61P 3/10** (2017.12); **A61P 5/14** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 11/02** (2017.12); **A61P 11/06** (2017.12); **A61P 13/08** (2017.12); **A61P 13/10** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 37/02** (2017.12); **A61P 37/06** (2017.12); **A61P 37/08** (2017.12); **C07K 16/24** (2013.01); **A61K 2039/505** (2013.01)

Citation (search report)

- [A] WO 2004045525 A2 20040603 - MOREHOUSE SCHOOL OF MEDICINE [US]
- [A] WO 2012082494 A2 20120621 - MOREHOUSE SCHOOL OF MEDICINE [US], et al
- [I] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 & FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638
- [A] JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240
- [A] FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S
- [A] RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783
- See references of WO 2014003742A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2014003742 A1 20140103**; CN 104870013 A 20150826; CN 112807427 A 20210518; EP 2866830 A1 20150506; EP 2866830 A4 20151209; HK 1212628 A1 20160617; JP 2015524793 A 20150827

DOCDB simple family (application)

**US 2012044464 W 20120627**; CN 201280075412 A 20120627; CN 201710770034 A 20120627; EP 12880044 A 20120627; HK 16100682 A 20160121; JP 2015520137 A 20120627